NodThera, the leading clinical-stage NLRP3 company developing a portfolio of best-in-class brain-penetrant and immune-targeted oral inhibitors to address cardiometabolic and neuroinflammatory diseases ...
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that managem ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する